ClinicalTrials.gg
TerminatedNCT00977379XERADUpdated Nov 15, 2016Results posted

A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis

A Phase 2 interventional study of WBRT and Capecitabine in Breast Cancer, sponsored by Hoffmann-La Roche. Terminated at 16 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to an insufficient number of participants enrolled.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Enrollment
176th of 227
24 · median 54
Started
2009
with 11 others
Phase 2
121 of 233
20 open now
Registered
110th of 233
by date
Lead sponsor
12 of 233
Hoffmann-La Roche

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 176th largest by enrollment of the 227 interventional ones that give a count, is one of 12 that started in 2009, is one of 121 in phase 2, and was the 110th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This open-label, randomized, parallel arm study will evaluate the effect of capecitabine administered concurrently with WBRT and as maintenance therapy in participants with breast cancer and newly diagnosed brain metastases. Participants will be randomized to receive either capecitabine with 10 days standard WBRT, or WBRT alone. Maintenance therapy will follow with capecitabine or another systemic therapy in the WBRT only group.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with confirmed breast cancer with known human epidermal receptor-2 () and hormone status
  • Newly diagnosed with at least one brain lesion measuring greater than or equal to (>/=) 1 centimeter (cm) or two lesions measuring >/= 0.5 to less than (\<) 1 cm in longest dimension
  • Participant not eligible for or refusing surgery or stereotactic radiosurgery
  • (EOCG) performance status 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Prior treatment of
  • Known to radiotherapy or magnetic resonance imaging (MRI) or capecitabine
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    WBRT Followed by Standard of Care

    Participants will receive 3000 centi-Gray (cGy) WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) followed by standard of care therapy at the discretion of the treating oncologist starting no earlier than 2 weeks after completion of WBRT. The participants will be followed during the treatment until the halting of standard of care for any reason (central nervous system \[CNS\] or extra-cranial tumor progression, unacceptable toxicity, change of therapeutic strategy, withdrawal of participant consent, or death).

    Radiation: WBRT · Drug: Standard of Care

  • Experimental
    WBRT+Capecitabine Followed by Capecitabine Maintenance

    Participants will receive 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) concurrent with capecitabine 825 milligrams per square meter (mg/m\^2) orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by capecitabine 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2, one week after completion of WBRT and continuing until the halting of capecitabine for any reason (CNS or extra-cranial progression, unacceptable toxicity, withdrawal of participant consent or death).

    Radiation: WBRT · Drug: Capecitabine

Interventions

  • RadiationWBRT

    3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).

  • 825 mg/m\^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.

    Also known as: Xeloda

  • DrugStandard of Care

    The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Best Objective Central Nervous System (CNS) Response, Assessed by Centralized Independent Expert According to Magnetic Resonance Imaging (MRI) - Intent-to-Treat (ITT) Population

    Best objective CNS response was defined as having complete response (CR) or partial response (PR) for CNS metastasis, assessed by contrast-enhanced MRI using response evaluation criteria in solid tumors (RECIST). CR: disappearance of all CNS lesions. PR: greater than or equal to (\>/=) 30 percent (%) decrease in sum of longest diameters (LD) of CNS lesions taking as reference the baseline sum LD.

    Time frame: Baseline until disease progression (PD), unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)

  2. Percentage of Participants With Best Objective CNS Response, Assessed by Centralized Independent Expert According to MRI - Per-Protocol (PP) Population

    Best objective CNS response was defined as having CR or PR for CNS metastasis, assessed by contrast-enhanced MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30% decrease in sum of LD of CNS lesions taking as reference the baseline sum LD.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)

Secondary outcomes

  1. Percentage of Participants With Objective CNS Response at 4 Weeks After Completion of WBRT, Assessed by Centralized Independent Expert According to MRI

    Objective CNS response was defined as having CR or PR for CNS metastasis, assessed by contrast-enhanced MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30% decrease in sum of LD of CNS lesions taking as reference the baseline sum LD.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first up to 4 weeks after completion of WBRT (up to approximately 7 weeks)

  2. Percentage of Participants With Best Objective CNS Response, Assessed by Investigator According to MRI

    Best objective CNS response was defined as having CR or PR for CNS metastasis, assessed by contrast-enhanced MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30% decrease in sum of LD of CNS lesions taking as reference the baseline sum LD.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)

  3. Percentage of Participants With Objective CNS Response at 4 Weeks After Completion of WBRT, Assessed by Centralized Independent Expert According to MRI in 3 Dimension

    Objective CNS response was defined as having CR or PR for CNS metastasis, assessed by 3 dimensional MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30% decrease in sum of LD of CNS lesions taking as reference the baseline sum LD.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first up to 4 weeks after completion of WBRT (up to approximately 7 weeks)

  4. Percentage of Participants With Clinical Benefit, Assessed by Investigator According to MRI

    Clinical benefit was defined as having CR, PR, or stable disease (SD), assessed by contrast-enhanced MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30 % decrease in sum of LD of CNS lesions taking as reference the baseline sum LD. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference smallest sum LD since treatment started. PD: a 20% or greater increase in the sum of the LD of CNS lesions taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more CNS lesions and/or unequivocal progression of existing CNS lesions.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)

  5. Percentage of Participants With Objective CNS Response at 4 Weeks After Completion of WBRT, Assessed by Investigator According to MRI

    Objective CNS response was defined as having CR or PR for CNS metastasis, assessed by contrast-enhanced MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30 % decrease in sum of LD of CNS lesions taking as reference the baseline sum LD.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first up to 4 weeks after completion of WBRT (up to approximately 7 weeks)

  6. Duration of CNS Response, Assessed by Investigator According to MRI

    Duration of CNS response was defined as the time from first documented cranial CR or PR (whichever was recorded first) until the first date CNS recurrence or progression was documented as assessed by contrast-enhanced MRI according to RECIST criteria but without exam for response confirmation. CR: disappearance of all CNS lesions. PR: \>/=30 % decrease in sum of LD of CNS lesions taking as reference the baseline sum LD. PD: a 20% or greater increase in the sum of the LD of CNS lesions taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more CNS lesions and/or unequivocal progression of existing CNS lesions.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)

  7. Time to CNS Progression, Assessed by Investigator According to MRI

    Time to CNS progression was defined as the time from start of study treatment to first documentation of PD or death due to CNS metastasis. PD was assessed by contrast-enhanced MRI according to RECIST. PD: a 20% or greater increase in the sum of the LD of CNS lesions taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more CNS lesions and/or unequivocal progression of existing CNS lesions.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)

  8. Percentage of Participants With Best Objective Extra-cranial Disease Response, Assessed by Investigator According to Computed Tomography (CT)

    Best objective extra-cranial response was defined as having CR or PR for extra-cranial lesions, assessed by CT using RECIST. CR: disappearance of all extra-cranial lesions. PR: \>/=30 % decrease in sum of LD of extra-cranial lesions taking as reference the baseline sum LD.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)

  9. Percentage of Participants With Objective Extra-cranial Disease Response at 4 Weeks After Completion of WBRT, Assessed by Investigator According to CT

    Objective extra-cranial response was defined as having CR or PR for extra-cranial lesions, assessed by CT using RECIST. CR: disappearance of all extra-cranial lesions. PR: \>/=30 % decrease in sum of LD of extra-cranial lesions taking as reference the baseline sum LD.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first up to 4 weeks after completion of WBRT (up to approximately 7 weeks)

  10. Time to Extra-cranial Disease Progression, Assessed by Investigator According to CT

    Time to extra-cranial progression was defined as the time from start of study treatment to first documentation of PD or death due to extra-cranial lesions. PD was assessed by CT according to RECIST. PD: a 20% or greater increase in the sum of the LD of extra-cranial lesions taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more extra-cranial lesions and/or unequivocal progression of existing extra-cranial lesions.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)

  11. Time to Progression, Assessed by Investigator According to MRI and CT

    Time to progression was defined as the time from start of study treatment to first documentation of PD or death due to tumor (CNS or extra-cranial). PD was assessed by MRI or CT according to RECIST. PD: a 20% or greater increase in the sum of the LD of CNS or extra-cranial lesions taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more CNS or extra-cranial lesions and/or unequivocal progression of existing CNS or extra-cranial lesions.

    Time frame: Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)

  12. Overall Survival (OS)

    OS was defined as the time from the start of study treatment to date of death due to any cause. OS was assessed using Kaplan-Meier analysis.

    Time frame: Baseline until death (up to approximately 1 year 5.5 months overall)

  13. Absolute Change From Baseline in Mini Mental State (MMS) Total Score

    MMS was an 11-question measure that tested five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. Four items were scored on a scale of 0 to 1; 1 item was scored on a scale of 0 to 2; 3 items were scored on a scale of 0 to 3; and 3 items were scored on a scale of 0 to 5. MMS total score was obtained by adding the scores of all individual items and ranged from 0 to 30, where higher scores indicate better cognitive state.

    Time frame: Baseline, Up to end of Treatment (up to 10.6 months overall)

07

Results

Posted Nov 15, 2016
Limitations and caveats
Study was prematurely terminated due to an insufficient number of participants enrolled and therefore results are only based on a small sample of breast cancer participants with newly diagnosed brain metastasis and should be considered with caution.

Participant flow

Participant flow — Overall Study
MilestoneWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Started1212
Treated1211
Completed00
Not completed1212
Withdrew: Withdrawal by subject11
Withdrew: Death79
Withdrew: Premature study termination40
Withdrew: Participant moving house01
Withdrew: Randomization error01

Outcome measures

PrimaryPercentage of Participants With Best Objective Central Nervous System (CNS) Response, Assessed by Centralized Independent Expert According to Magnetic Resonance Imaging (MRI) - Intent-to-Treat (ITT) Population

Best objective CNS response was defined as having complete response (CR) or partial response (PR) for CNS metastasis, assessed by contrast-enhanced MRI using response evaluation criteria in solid tumors (RECIST). CR: disappearance of all CNS lesions. PR: greater than or equal to (\>/=) 30 percent (%) decrease in sum of longest diameters (LD) of CNS lesions taking as reference the baseline sum LD.

Time frame:
Baseline until disease progression (PD), unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Objective Central Nervous System (CNS) Response, Assessed by Centralized Independent Expert According to Magnetic Resonance Imaging (MRI) - Intent-to-Treat (ITT) Population
percentage of participantsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Percentage of Participants With Best Objective Central Nervous System (CNS) Response, Assessed by Centralized Independent Expert According to Magnetic Resonance Imaging (MRI) - Intent-to-Treat (ITT) Population25.036.4
PrimaryPercentage of Participants With Best Objective CNS Response, Assessed by Centralized Independent Expert According to MRI - Per-Protocol (PP) Population

Best objective CNS response was defined as having CR or PR for CNS metastasis, assessed by contrast-enhanced MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30% decrease in sum of LD of CNS lesions taking as reference the baseline sum LD.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Objective CNS Response, Assessed by Centralized Independent Expert According to MRI - Per-Protocol (PP) Population
percentage of participantsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Percentage of Participants With Best Objective CNS Response, Assessed by Centralized Independent Expert According to MRI - Per-Protocol (PP) Population20.033.3
SecondaryPercentage of Participants With Objective CNS Response at 4 Weeks After Completion of WBRT, Assessed by Centralized Independent Expert According to MRI

Objective CNS response was defined as having CR or PR for CNS metastasis, assessed by contrast-enhanced MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30% decrease in sum of LD of CNS lesions taking as reference the baseline sum LD.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first up to 4 weeks after completion of WBRT (up to approximately 7 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective CNS Response at 4 Weeks After Completion of WBRT, Assessed by Centralized Independent Expert According to MRI
percentage of participantsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Percentage of Participants With Objective CNS Response at 4 Weeks After Completion of WBRT, Assessed by Centralized Independent Expert According to MRI25.036.4
SecondaryPercentage of Participants With Best Objective CNS Response, Assessed by Investigator According to MRI

Best objective CNS response was defined as having CR or PR for CNS metastasis, assessed by contrast-enhanced MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30% decrease in sum of LD of CNS lesions taking as reference the baseline sum LD.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Objective CNS Response, Assessed by Investigator According to MRI
percentage of participantsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Percentage of Participants With Best Objective CNS Response, Assessed by Investigator According to MRI50.054.5
SecondaryPercentage of Participants With Objective CNS Response at 4 Weeks After Completion of WBRT, Assessed by Centralized Independent Expert According to MRI in 3 Dimension

Objective CNS response was defined as having CR or PR for CNS metastasis, assessed by 3 dimensional MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30% decrease in sum of LD of CNS lesions taking as reference the baseline sum LD.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first up to 4 weeks after completion of WBRT (up to approximately 7 weeks)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Clinical Benefit, Assessed by Investigator According to MRI

Clinical benefit was defined as having CR, PR, or stable disease (SD), assessed by contrast-enhanced MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30 % decrease in sum of LD of CNS lesions taking as reference the baseline sum LD. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference smallest sum LD since treatment started. PD: a 20% or greater increase in the sum of the LD of CNS lesions taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more CNS lesions and/or unequivocal progression of existing CNS lesions.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Benefit, Assessed by Investigator According to MRI
percentage of participantsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Percentage of Participants With Clinical Benefit, Assessed by Investigator According to MRI83.372.7
SecondaryPercentage of Participants With Objective CNS Response at 4 Weeks After Completion of WBRT, Assessed by Investigator According to MRI

Objective CNS response was defined as having CR or PR for CNS metastasis, assessed by contrast-enhanced MRI using RECIST. CR: disappearance of all CNS lesions. PR: \>/=30 % decrease in sum of LD of CNS lesions taking as reference the baseline sum LD.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first up to 4 weeks after completion of WBRT (up to approximately 7 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective CNS Response at 4 Weeks After Completion of WBRT, Assessed by Investigator According to MRI
percentage of participantsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Percentage of Participants With Objective CNS Response at 4 Weeks After Completion of WBRT, Assessed by Investigator According to MRI41.727.3
SecondaryDuration of CNS Response, Assessed by Investigator According to MRI

Duration of CNS response was defined as the time from first documented cranial CR or PR (whichever was recorded first) until the first date CNS recurrence or progression was documented as assessed by contrast-enhanced MRI according to RECIST criteria but without exam for response confirmation. CR: disappearance of all CNS lesions. PR: \>/=30 % decrease in sum of LD of CNS lesions taking as reference the baseline sum LD. PD: a 20% or greater increase in the sum of the LD of CNS lesions taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more CNS lesions and/or unequivocal progression of existing CNS lesions.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)
Reported as:
Median · months
Duration of CNS Response, Assessed by Investigator According to MRI
monthsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Duration of CNS Response, Assessed by Investigator According to MRI6.2 (0 to 16)2.6 (0 to 11)
SecondaryTime to CNS Progression, Assessed by Investigator According to MRI

Time to CNS progression was defined as the time from start of study treatment to first documentation of PD or death due to CNS metastasis. PD was assessed by contrast-enhanced MRI according to RECIST. PD: a 20% or greater increase in the sum of the LD of CNS lesions taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more CNS lesions and/or unequivocal progression of existing CNS lesions.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)
Reported as:
Median · months
Time to CNS Progression, Assessed by Investigator According to MRI
monthsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Time to CNS Progression, Assessed by Investigator According to MRI3.8 (1 to 17)3.4 (1 to 15)
SecondaryPercentage of Participants With Best Objective Extra-cranial Disease Response, Assessed by Investigator According to Computed Tomography (CT)

Best objective extra-cranial response was defined as having CR or PR for extra-cranial lesions, assessed by CT using RECIST. CR: disappearance of all extra-cranial lesions. PR: \>/=30 % decrease in sum of LD of extra-cranial lesions taking as reference the baseline sum LD.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Objective Extra-cranial Disease Response, Assessed by Investigator According to Computed Tomography (CT)
percentage of participantsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Percentage of Participants With Best Objective Extra-cranial Disease Response, Assessed by Investigator According to Computed Tomography (CT)0.09.1
SecondaryPercentage of Participants With Objective Extra-cranial Disease Response at 4 Weeks After Completion of WBRT, Assessed by Investigator According to CT

Objective extra-cranial response was defined as having CR or PR for extra-cranial lesions, assessed by CT using RECIST. CR: disappearance of all extra-cranial lesions. PR: \>/=30 % decrease in sum of LD of extra-cranial lesions taking as reference the baseline sum LD.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first up to 4 weeks after completion of WBRT (up to approximately 7 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Extra-cranial Disease Response at 4 Weeks After Completion of WBRT, Assessed by Investigator According to CT
percentage of participantsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Percentage of Participants With Objective Extra-cranial Disease Response at 4 Weeks After Completion of WBRT, Assessed by Investigator According to CT0.09.1
SecondaryTime to Extra-cranial Disease Progression, Assessed by Investigator According to CT

Time to extra-cranial progression was defined as the time from start of study treatment to first documentation of PD or death due to extra-cranial lesions. PD was assessed by CT according to RECIST. PD: a 20% or greater increase in the sum of the LD of extra-cranial lesions taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more extra-cranial lesions and/or unequivocal progression of existing extra-cranial lesions.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)
Reported as:
Median · months
Time to Extra-cranial Disease Progression, Assessed by Investigator According to CT
monthsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Time to Extra-cranial Disease Progression, Assessed by Investigator According to CT3.5 (1 to 10)2.7 (1 to 15)
SecondaryTime to Progression, Assessed by Investigator According to MRI and CT

Time to progression was defined as the time from start of study treatment to first documentation of PD or death due to tumor (CNS or extra-cranial). PD was assessed by MRI or CT according to RECIST. PD: a 20% or greater increase in the sum of the LD of CNS or extra-cranial lesions taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more CNS or extra-cranial lesions and/or unequivocal progression of existing CNS or extra-cranial lesions.

Time frame:
Baseline until PD, unacceptable toxicity, withdrawal of consent, change of therapeutic strategy (for arm "WBRT Followed by Standard of Care" only), or death, whichever occurred first (up to approximately 1 year 5.5 months overall)
Reported as:
Median · months
Time to Progression, Assessed by Investigator According to MRI and CT
monthsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Time to Progression, Assessed by Investigator According to MRI and CT3.3 (1 to 10)2.7 (1 to 15)
SecondaryOverall Survival (OS)

OS was defined as the time from the start of study treatment to date of death due to any cause. OS was assessed using Kaplan-Meier analysis.

Time frame:
Baseline until death (up to approximately 1 year 5.5 months overall)
Reported as:
Median · months
Overall Survival (OS)
monthsWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Overall Survival (OS)9.8 (4.3 to 17.0)4.6 (2.3 to 8.9)
SecondaryAbsolute Change From Baseline in Mini Mental State (MMS) Total Score

MMS was an 11-question measure that tested five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. Four items were scored on a scale of 0 to 1; 1 item was scored on a scale of 0 to 2; 3 items were scored on a scale of 0 to 3; and 3 items were scored on a scale of 0 to 5. MMS total score was obtained by adding the scores of all individual items and ranged from 0 to 30, where higher scores indicate better cognitive state.

Time frame:
Baseline, Up to end of Treatment (up to 10.6 months overall)
Reported as:
Mean · units on a scale
Absolute Change From Baseline in Mini Mental State (MMS) Total Score
units on a scaleWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
Absolute Change From Baseline in Mini Mental State (MMS) Total Score-1.5 ± 4.30.9 ± 3.2

Adverse events

Collected over Throughout study (up to approximately 1 year 5.5 months overall). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
WBRT Followed by Standard of Care—6/12 (50%)11/12 (91.7%)
WBRT+Capecitabine Followed by Capecitabine Maintenance—6/11 (54.5%)10/11 (90.9%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
General physical health deteriorationGeneral disorders1/122/11
ColitisGastrointestinal disorders0/121/11
Depressed level of consciousnessNervous system disorders0/121/11
EpilepsyNervous system disorders1/121/11
Intracranial pressure increasedNervous system disorders0/121/11
SyncopeNervous system disorders0/121/11
Completed suicidePsychiatric disorders0/121/11
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/121/11
AstheniaGeneral disorders1/120/11
Chest painGeneral disorders1/120/11
Most frequent other events
Showing 10 of 66
Most frequent other events
EventWBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine Maintenance
VomitingGastrointestinal disorders1/126/11
HeadacheNervous system disorders6/126/11
AstheniaGeneral disorders6/125/11
NauseaGastrointestinal disorders4/125/11
AlopeciaSkin and subcutaneous tissue disorders4/122/11
DiarrhoeaGastrointestinal disorders1/123/11
FatigueGeneral disorders0/123/11
Decreased AppetiteMetabolism and nutrition disorders3/122/11
LeukopeniaBlood and lymphatic system disorders3/121/11
Balance DisorderNervous system disorders0/122/11

Baseline characteristics

Intent to treat (ITT) population included all randomized participants except one participant from "WBRT+Capecitabine Followed by Capecitabine Maintenance" arm who was randomized by error.

Age, Continuous
Age, Continuous(years)WBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine MaintenanceTotal
Mean54.8 ± 15.657.8 ± 13.156.2 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)WBRT Followed by Standard of CareWBRT+Capecitabine Followed by Capecitabine MaintenanceTotal
Female121123
Male000
08

Study locations

16 sites
  • Arras, 62000, France
  • Beuvry, 62660, France
  • Beziers, 34500, France
  • Bobigny, 93009, France
  • Dijon, 21079, France
  • Le Mans, 72015, France
  • Lille, 59020, France
  • Lyon, 69373, France
  • Montpellier, 34928, France
  • Nantes, 44202, France
  • Narbonne, 11780, France
  • Nice, 06000, France
  • Paris, 75475, France
  • Paris, 75651, France
  • Rouen, 76000, France
  • Salouel, 80480, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2009
First posted
Sep 15, 2009
Start
Aug 2009
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results first posted
Nov 15, 2016
Last update
Nov 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00977379
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 15, 2009
Start date
Aug 2009
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
Nov 15, 2016
Last update
Nov 15, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion